#AACR17 roundup: Bristol-Myers, Merck KGaA and Pfizer in the spotlight, marking progress with checkpoints
PHOTO: © AACR/Todd Buchanan 2017
Bristol-Myers IDs a subset of patients who see a durable, 5-year response to Opdivo
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
